2 completed, 1 withdrawn. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
Follow LGK974: new trials by email Literature Review of LGK974 trials Research Report on LGK974
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations WNT974, LGX818, Cetuximab - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Completed | Array BioPharma | 20 | 2014-12-01 | 2017-10-09 |
| A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands LGK974, PDR001 - Pancreatic Cancer, BRAF Mutant Colorectal Cancer | Phase 1 | Completed | Novartis Pharmaceuticals | 185 | 2011-12-01 | 2025-06-13 |
| A Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma WNT974 - Squamous Cell Carcinoma, Head And Neck | Phase 2 | Withdrawn | University of Michigan Rogel Cancer Center | 2016-09-30 |
Colorectal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Melanoma (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Triple Negative Breast Neoplasms (1)
Array BioPharma (1) · Novartis Pharmaceuticals (1) · University of Michigan Rogel Cancer Center (1)
United States (3) · Canada (2) · France (2) · Italy (2) · Netherlands (2) · Spain (2) · Australia (1) · Belgium (1) · Germany (1) · Israel (1) · Singapore (1)